Bio-Bridge Science to Relocate Headquarters to Oakbrook Terrace, Illinois, USA

Bio-Bridge Science, Inc. (OTCBB: BGES), a biotechnology company engaged in the commercial development of biological products for the prevention and treatment of human diseases and manufacturing and sales of materials used during vaccine production, announced today that it plans to move its corporate headquarters from Oak Brook, Illinois to the neighboring City of Oakbrook Terrace, Illinois by September 2010. The new location offers the company an increase in office space, a significant reduction in cost per square foot, and greater flexibility in space requirements and utilization.

“This decision reflects our need to be able to expand or adapt to changes in our business while maintaining costs at a reasonable level. We have enjoyed our time in Oak Brook; however, the objective is to increase our office space while reducing the cost per square foot and we felt Oakbrook Terrace met this objective better,” said Dr. Liang Qiao, CEO.

About Bio-Bridge Science

Bio-Bridge Science is currently developing products including an HIV vaccine, a colon cancer therapeutic vaccine, and an HPV vaccine. Additionally, the company sells bovine serum, a material used in vaccine production through its subsidiary, Bio-Bridge Xinheng Baide Biotechnology. The Company's 51% owned joint venture, Bio-Bridge JRS Biosciences, will produce cell-culture medium which is also a material used in vaccine production. For more information please visit http://www.bio-bridge-science.com/.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to the Company's SEC filings for additional information.